Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ALXN1840 copper balance study in adults with Wilson disease
2020-001104-41Phase 2Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atn-224 in Wilson disease (WD) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Mean daily copper balance. Status: unknown.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2020-001104-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001104-41.